Cannabinoids Are Neuroprotective in a Human Cell Culture Model of Parkinson's Disease by Carroll, CB et al.
role in psychiatric disease. We have conducted a systematic review
of previous publications detailing SGCE mutation status and
psychiatric disease. Inclusion criteria included: use of recognised
MDS diagnostic criteria, a case control study design, SGCE status,
and the use of standardised and validated psychiatric assessment
tools. When data were pooled, these showed a signiﬁcant associa-
tion between SGCE mutations and psychiatric disease (p¼0.028),
including obsessive-compulsive disorders, depression and generalised
anxiety disorder. This association was further strengthened when
inclusion criteria were relaxed to include details of psychiatric
diagnoses obtained by clinical history or patient self-report
(p¼0.012). This supports the view that psychiatric disorders form
part of the MDS phenotype and that epsilon-sarcoglycan may have
an important role to play.
POMD11 CANNABINOIDS ARE NEUROPROTECTIVE IN A HUMAN
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Background We have previously shown a protective effect of D9-
tetrahydrocannabinol (THC) in Parkinson’s disease (PD) cell culture
models associated with increased CB1 cannabis receptor cDNA.
Here we investigate whether this protective effect is mediated via
the CB1 receptor.
Methods SH-SY5Y human neuroblastoma cells were differentiated
to a neuronal phenotype. The presence of an endocannabinoid
system (ECS) was investigated by immunocytochemistry, Western
blotting and reverse transcriptase PCR. Cannabinoids and ECS
modulators were co-administered with PD-relevant toxins (MPP+
(mitochondrial inhibitor), lactacystin (proteasome inhibitor), para-
quat (free radical generator) to determine any protective effect.
Results The protective effect of D9-THC was not blocked by the
CB1 antagonist AM251, nor reproduced by the CB1 agonist
WIN55,212-2. D9-THC is known to be antioxidant. Cannabidiol, an
antioxidant with little CB1 receptor afﬁnity, exerted a protective
effect against MPP+ with no effect against paraquat or lactacystin.
Cannabidiol may be acting via modulation of anandamide hydrol-
ysis. We found expression of the enzyme involved in endocannabi-
noid hydrolysis, fatty-acid amide hydrolase (FAAH). Co-
administration of URB597, an FAAH inhibitor, was protective
against MPP+, an effect which was not blocked by antagonism of
the CB1 receptor.
Conclusions Our results suggest that the protective effects of
cannabinoids in cell culture models of PD may be mediated by
modulation of the ECS.
POMD12 VISUAL CUE “WALKING GLASSES” MAY AID GAIT IN
PARKINSON’S DISEASE
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Gait disturbance is an almost universal complaint suffered by PD
patients as they inevitably progress to the more severe stages of the
disease. This can be partially corrected by external cues guiding
placement of each step. “Walking glasses”, spectacles that present
the patient with visual cues to aid walking without necessitating
marking the ﬂoor or using a walking stick, have been used with
varying degrees of success. We explored the use of a novel design of
walking glasses that provide ﬂexibility of visual and auditory cueing
and would be very cheap to mass-produce. Performance was meas-
ured by timing 15 Parkinson’s disease patients’ walking over a “real-
life” predeﬁned 30 m course using different patterns of visual and
auditory stimulation. Using the glasses, 8 of 15 patients achieved a
meaningful beneﬁt in walking speed of 21.5% (95% CI 3.9%). A
further two patients had subjective beneﬁt. It was found that both
visual and auditory cues were beneﬁcial, different patterns suiting
different patients and more effective in different circumstances.
Overall, the best pattern was visual cueing alone with a ﬁxed cue
present all the time. This pilot study shows promising improvement
in the gait of a signiﬁcant proportion of Parkinson’s disease patients
through the use of a simple, inexpensive and robust design of
walking glasses, suggesting practical applicability in a therapy
setting to large numbers of such patients.
POMD13 DISTINGUISHING TREMOR-DOMINANT PARKINSON’S
DISEASE FROM TREMULOUS SUBJECTS WITHOUT
EVIDENCE OF DOPAMINERGIC DEFICIT BY SPIROGRAPHY:
AN FP-CIT VALIDATED STUDY
doi:10.1136/jnnp.2010.226340.173
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Five to ﬁfteen per cent of de novo patients recruited for recent
clinical trials of anti-parkinsonian drugs had no evidence of nigros-
triatal dopamine denervation on functional imaging. These diag-
nostically challenging subjects without evidence of dopaminergic
deﬁcit (SWEDDs) had tremulous syndromes other than Parkinson’s
disease (PD). Our objective was to analyse the accuracy of spirog-
raphy in distinguishing cases of tremor dominant PD from trem-
ulous SWEDDs cases. Analyses were carried out by observers
blinded to the clinical data and supplied with just spiral drawings,
from which tremor severity, 3-turn spiral diameter and spiral density
were measured. A spiral coefﬁcient, averaged for the spirals drawn
by each hand, was derived from these three indices. A cut off of <4
in the coefﬁcient was taken to indicate PD. Of the 65 cases analysed,
the data were felt to be of insufﬁcient quality in 6. Of the remaining
59 cases, the sensitivity and speciﬁcity for differentiating tremor
dominant PD from tremulous SWEDDs was 65.2% and 61.1%
respectively. An analysis was also performed looking at the indi-
vidual spiral components. This showed that the sensitivity and
speciﬁcity for tremor severity were 62.5% and 74.3%, 3-turn diam-
eter 75% and 77.8% and spiral density 28% and 67.3% respectively
for predicting PD. The simple 3-turn spiral diameter has similar
sensitivity and speciﬁcity for distinguishing PD from SWEDDs as
reported for two blind PD experts assessing these patients from
standardised videotapes.
PONM01 MEASUREMENT OF GLOBAL STRENGTH: STABLE CONCEPT,
FLUID RULER
doi:10.1136/jnnp.2010.226340.174
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Background We previously described the construction of a measure
for global strength in MS. However, loss of strength is common to
many diseases. Thus, a generic strength measure may prove widely
applicable and allow inter-disease comparison.
Aim To determine whether measurement performance of the MS-
derived strength scale remained stable in people with CIDP.
Method MRC strength data from the RMC study (n¼238) were
amalgamated with those from our previously described MS sample
(n¼371). Items included were the eight pairs of muscles (four upper
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